A Case of Adult Multisystem Inflammatory Syndrome Following COVID-19 Vaccine

Meghan Brown
Mayo Clinic, Rochester, Minnesota, USA

Nika Zorko Garbajs
Mayo Clinic, Rochester, Minnesota, USA

Simon Zec
Mayo Clinic, Rochester, Minnesota, USA

Hisham Mushtaq
Mayo Clinic Health System, Mankato, USA

Anwar Khedr
Mayo Clinic Health System, Mankato, USA

Follow this and additional works at: https://scholarlycommons.gbmc.org/jchimp

Related Commons: Critical Care Commons, Immune System Diseases Commons, Infectious Disease Commons, Internal Medicine Commons, Other Medical Specialties Commons, Other Public Health Commons, Preventive Medicine Commons, and the Virus Diseases Commons

Recommended Citation
Brown, Meghan; Garbajs, Nika Zorko; Zec, Simon; Mushtaq, Hisham; Khedr, Anwar; Jama, Abbas Bashir; Rauf, Ibtisam; Mir, Mikael; Korsapati, Aishwarya Reddy; Jain, Shikha; Koritala, Thoyaja; Adhikari, Ramesh; Lal, Amos; Gajic, Ognjen; Domecq, Juan Pablo; Goksoy, Sarah; Bartlett, Brian; Sharma, Amit; Jain, Nitesh Kumar; and Khan, Syed Anjum (2022) "A Case of Adult Multisystem Inflammatory Syndrome Following COVID-19 Vaccine," Journal of Community Hospital Internal Medicine Perspectives: Vol. 12: Iss. 4, Article 2.
DOI: 10.55729/2000-9666.1087
Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss4/2

This Case Report is brought to you for free and open access by the Journal at GBMC Healthcare Scholarly Commons. It has been accepted for inclusion in Journal of Community Hospital Internal Medicine Perspectives by an authorized editor of GBMC Healthcare Scholarly Commons. For more information, please contact GBMCcommons@gbmc.org.
A Case of Adult Multisystem Inflammatory Syndrome Following COVID-19 Vaccine

Authors
Meghan Brown, Nika Zorko Garbajs, Simon Zec, Hisham Mushtaq, Anwar Khedr, Abbas Bashir Jama, Ibtisam Rauf, Mikael Mir, Aishwarya Reddy Korsapati, Shikha Jain, Thoyaja Koritala, Ramesh Adhikari, Amos Lal, Ognjen Gajic, Juan Pablo Domecq, Sarah Goksoy, Brian Bartlett, Amit Sharma, Nitesh Kumar Jain, and Syed Anjum Khan

This case report is available in Journal of Community Hospital Internal Medicine Perspectives: https://scholarlycommons.gbm.org/jchimp/vol12/iss4/2
A Case of Adult Multisystem Inflammatory Syndrome Following COVID-19 Vaccine

Meghan Brown a,1, Nika Z. Garbajsa a,1, Simon Zec a, Hisham Mushtaq b, Anwar Khedr b, Abbas B. Jama b, Ibtsam Rauf c, Mikael Mir h, Aishwarya R. Korsapati d, Shikha Jain e, Thoyaja Koritala b, Ramesh Adhikari f, Amos Lal a, Ognjen Gajic a, Juan Pablo Domecq a, Sarah Goksoy g,*, Brian Bartlett b, Amit Sharma i, Nitesh Kumar Jain b,*, Syed Anjum Khan b

a Mayo Clinic, Rochester, MN, USA
b Mayo Clinic Health System, Mankato, USA
c St George’s University, True Blue, Grenada
d University of Buckingham Medical School, London, United Kingdom
e MVJ Medical College and Research Hospital, Bengaluru, India
f Franciscan Health Lafayette East, Lafayette, IN, USA
g University of California, Berkeley, CA, USA
h University of Minnesota, Duluth, MN, USA
i Geisinger Community Medical Center, Scranton, PA, USA

Abstract

Multisystem inflammatory syndrome is a life-threatening condition associated with elevated inflammatory markers and multiple organ injury. A diagnosis of exclusion, it has been reported after severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) in children and adults; recently it has been described in some post-COVID-19 vaccinated individuals. The prognosis with supportive care and immunomodulatory therapy is good, although some individuals may require treatment in the intensive care unit (ICU). Here we report a case of a 58-year-old man who developed multi-organ failure after receiving the second dose of the Moderna mRNA-1273 COVID-19 vaccine. He required critical organ support in the ICU. An extensive workup was done to rule out alternative infectious and inflammatory processes. Following a period of gradual in-hospital convalescence, our patient made a full recovery. To our knowledge, this is the first comprehensively described case of multisystem inflammatory syndrome associated with Moderna mRNA-1273 COVID-19 vaccine in an adult over 50 years of age.

Keywords: COVID-19 vaccine, Multisystem inflammatory syndrome in adults (MIS-A), Multisystem inflammatory syndrome in vaccinated individuals (MIS-V), Immunological products and vaccines, Intensive care, Vaccination/immunization, Acute tubular necrosis (ATN), Unwanted effects/Adverse reactions

1. Introduction

Multisystem inflammatory syndrome in children (MIS-C) was first reported in England followed by other countries around the world.1 It has been found to occur typically 4–6 weeks and up to 12 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, more commonly in healthy non-Hispanic black children, with multiple organ involvement and has a favorable prognosis.1,2 The syndrome is significant for involvement of the gastrointestinal tract (nausea, vomiting, diarrhea), cardiovascular system (circularity shock, elevated troponin, myocarditis), renal system (AKI), mucocutaneous lesions, conjunctivitis, lymphadenopathy, alongside constitutional symptoms like fever and anorexia.1–2 Patients have a hyperinflammatory milieu with some resemblance
to Kawasaki disease, but the latter occurs predominantly in younger children (less than 3 years old). Treatment generally has been supportive care with immunomodulatory treatment consisting of corticosteroid and intravenous immunoglobulin (IVIG).1–3

Multisystem inflammatory syndrome in adults (MIS-A) has also been described, with a far lower incidence compared to MIS-C.1–3 Compared to patients experiencing acute SARS-CoV-2 infection, these patients have a positive SARS-CoV-2 serology or recent infection and of note, absent or very minimal pulmonary symptoms.1,4,5 Like MIS-C, adults experiencing this syndrome have a hyperinflammatory milieu and multiple organ involvement, often needing critical care support along with immunomodulatory therapy. Antibody testing may establish the diagnosis if SARS-CoV-2 antigen or PCR testing is not available or negative.1,5,4 In adults, the clinical presentation of MIS-A could be broad and therefore, it may be under-recognized and under-reported.4,5 MIS following SARS-CoV-2 has demonstrated a consistently good response to steroids and/or IVIG.5,7

COVID-19 vaccinations play a crucial role in controlling the pandemic. As of February 14, 2022, more than 547 million doses of SARS-CoV-2 vaccine have been administered in the United States.8 The validation and production of COVID-19 vaccines were expedited in response to the rapid spread of SARS-CoV-2. Most post-vaccination reactions occur within 3 days of receiving a dose and resolve within 1–2 days.7,9 While MIS can usually be seen up to 12 weeks following SARS-CoV-2 infection, recently a handful of vaccine-associated cases have been reported in patients who likely had prior SARS-COV-2 infection.3,4,5,7,10,11 Vaccine-related MIS (MIS-V) has been reported in medical literature with both mRNA vaccine [Pfizer-Biontech, Moderna] and conventional inactivated vaccine [BIBP-CoV (Sinopharm)] with good clinical description.3,4,5,7,11 Despite generally self-limiting, some individuals affected by MIS-V have required critical organ support in the intensive care unit (ICU). Here we report a case of a middle-aged individual who developed shock with multi-organ failure and persistent encephalopathy temporally associated with SARS-CoV-2 vaccination.

2. Case presentation

A 58-year Caucasian man with a past medical history of obesity (body mass index of 33), gastroesophageal reflux disease, and chronic back pain presented to the emergency department with a 7-day history of headache, generalized weakness, nausea, and myalgias followed by a 1-day history of chills, profuse sweats, a fever in the range of 37.2–38.1 °C, and diarrhea. At presentation, he complained of progressive shortness of breath alongside vague abdominal pain and cramping, anorexia, and a rash on his lower extremities and back. He denied any prior dermatologic or rheumatologic conditions. He endorsed recent contact with livestock, domestic and wild animals, but denied any sick contacts or tick bites. Symptoms started one day after receiving the second dose of mRNA-1273 vaccine. He had received influenza, tetanus/diphtheria/pertussis, and hepatitis B vaccines in the past without adverse reactions and had no history of allergies. He denied any previous symptoms suggestive of SARS-CoV-2 infection, although a close contact did test positive for the same about 7 months prior to this presentation. He was a non-smoker, frequently consumed moderate amounts of alcohol, and regularly took acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs). At the onset of symptoms, a polymerase–chain reaction (PCR) testing was negative for SARS-CoV-2.

On admission he was afebrile (35.5 °C), mildly tachypneic (22/min) with abdominal breathing, but normal oxygen saturation on room air, tachycardic

Abbreviations

| Ab | antibody |
| AKI | acute kidney injury |
| ANCA | antineutrophil cytoplasmic antibodies |
| ATN | acute tubular necrosis |
| CDC | Centers for Disease Control and Prevention |
| COVID-19 | coronavirus disease 2019 |
| CSF | cerebrospinal fluid |
| CT | computed tomography |
| CT | computed tomography |
| HHV | human herpesvirus |
| HIV | human immunodeficiency virus |
| HSV | herpes simplex virus |
| ICU | intensive care unit |
| IVIG | intravenous immunoglobulin |
| MIS | multisystem inflammatory syndrome |
| MRI | magnetic resonance imaging |
| mRNA | messenger ribonucleic acid |
| NSAID | non-steroidal anti-inflammatory drugs |
| PCR | polymerase–chain reaction |
| RV | right ventricle |
| SARS-CoV-2 | Severe acute Respiratory Syndrome Coronavirus-2 |
(Heart rate: 100/minutes), and normotensive (Blood pressure: 110/70 mm Hg). There was presence of mild scleral icterus, and mild generalized abdominal tenderness. An erythematous confluent blanching rash sparing his palms and soles was noted on his lower extremities and back (Fig. 1). His mucous membranes appeared normal. Although, physical examination and radiological studies demonstrated no evidence of pulmonary parenchymal disease, his declining respiratory status, increased work of breathing and progressive encephalopathy necessitated ICU admission, noninvasive ventilation, and subsequent intubation with mechanical ventilation. Upon arrival in the ICU, he was hypotensive and required ample fluid resuscitation (8 L) with dual vasopressor support, and broad-spectrum antibiotics were initiated. His shock was thought to be a combination of distributive and more likely cardiogenic shock.

Given his history and clinical presentation, the differential diagnosis was very broad and is listed in Table 1. Chest X-ray and computed tomography

| Etiology                  | Condition                                                                 |
|---------------------------|---------------------------------------------------------------------------|
| Infectious                | • Septic shock of unknown origin.                                          |
|                           | • Toxic shock syndrome.                                                    |
|                           | • Staphylococcal and Streptococcal syndromes including Staphylococcal  |
|                           |   scalded skin syndrome, Scarlet fever.                                    |
|                           | • Gastrointestinal tract infections such as Campylobacter, C. difficile  |
|                           |   toxin, Plesiomonas shigelloides, Salmonella species, Vibrio species,   |
|                           |   Vibrio cholerae, Yersinia species, Enteroinvasive E. coli (EAEC),     |
|                           |   Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga  |
|                           |   toxin producing E. coli, Shigella/Enteroinvasive E. coli, Cryptosporidium |
|                           |   species, Cyclospora cayetanensis, Entamoeba histolytica, Giardia,      |
|                           |   Astrovirus, Norovirus GI/GII, Rotavirus Ag, Sapovirus.                  |
|                           | • Tick-borne illnesses such as Lyme disease, Anaplasmosis, Babesiosis,    |
|                           |   Tularemia, Ehrlichiosis, and Rickettsia.                                 |
|                           | • Bacterial/Viral meningoencephalitis including Adenovirus, Coronavirus,  |
|                           |   SARS Coronavirus-2, Human Metapneumovirus, Human Rhinovirus/Enterovirus,|
|                           |   Influenza A, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2,|
|                           |   Parainfluenza Virus 3, Parainfluenza Virus 4, Respiratory Syncytial    |
|                           |   Virus, Bordetella parapertussis, Bordetella pertussis, Chlamydia         |
|                           |   pneumoniae, Mycoplasma pneumoniae, West Nile virus infection.            |
|                           | • Diseases associated with animal exposure such as Leptospirosis, Bartonella,|
|                           |   Brucella, Q fever, Francisella tularensis.                              |
|                           | • Viral diseases such as Epstein Barr virus, Enterovirus, Adenovirus,     |
|                           |   Parvovirus, Measles, Acute and Chronic viral hepatitis, Hanta virus.    |
|                           | • Endemic fungi such as Histoplasma, Blastomycyces.                       |
|                           | • HIV.                                                                    |
|                           | • Malaria and Toxoplasmosis.                                              |
| Vasculitis                 | • Cryoglobulinemia.                                                       |
|                           | • Rheumatoid arthritis.                                                   |
|                           | • Systemic Lupus erythematosus.                                           |
|                           | • ANCA associated Vasculitis.                                             |
|                           | • Goodpasture's syndrome                                                  |
| Miscellaneous             | • Drug reaction with eosinophilia and systemic symptoms (DRESS)           |
|                           | • Macrophage activation syndrome                                          |
|                           | • Hemophagocytic lymphohistiocytosis (HLH)                               |
|                           | • Multisystem Inflammatory Syndrome (MIS-A, MIS-V).                       |
|                           | • Vaccine-induced immune reaction                                         |
| Causes of Acute Kidney    | • Acute glomerulonephritis secondary to infectious/noninfectious etiology  |
| injury (AKI)              | • Acute tubular necrosis/injury (ATN) secondary to Sepsis, hypotension    |
|                           |   and NSAIDs use.                                                        |
|                           | • Acute interstitial nephritis                                            |
|                           | • Thrombotic microangiopathy                                              |
|                           | • Non-monoclonal renal amyloid deposit                                    |
(CT) angiogram of the chest ruled out pulmonary embolism and showed no evidence of acute pulmonary parenchymal disease. Abdominal CT showed nonspecific bilateral fascial thickening, mesenteric fat stranding and lymph node enlargement, mild splenomegaly along with some dilated small bowel loops suggestive of localized ileus. Electrocardiogram performed serially showed normal sinus rhythm with ST segment elevation in anterolateral leads (Fig. 2). Echocardiogram showed elevated right ventricular (RV) systolic pressure, moderately enlarged RV chamber size and hypokinesis; mildly increased concentric left ventricular wall thickness with grade 2/3 left ventricular diastolic dysfunction, and an ejection fraction of 45%. There was no pericardial effusion. Coronary angiogram showed no significant coronary artery stenosis. Magnetic resonance cholangiopancreatography ruled out any evidence of biliary obstruction.

Initial and subsequent abnormal laboratory results are enumerated in Table 2. There was a mild to moderate decrease in hemoglobin and platelet count without evidence of intravascular hemolysis or microangiopathic hemolytic anemia. An exhaustive infectious/auto immune/rheumatological disease work up including but not limited to GI pathogen panel, Respiratory viral panel, Tick borne panel, Rodent borne panel, Meningitis/encephalitis panel, work up for Facultative intracellular bacteria, intra erythrocytic parasites, Fungal infection panel, work up for diseases associated with animal exposure such as Leptospirosis, Bartonella, Brucella, Q fever, Francisella tularensis; Parasitic infection panel, Viral infection panel, Acute and Chronic hepatitis panel, HIV testing, auto immune and rheumatological panel, work up for atypical bacterial pneumonia, was found to be negative.

Fig. 2. Electrocardiogram on admission which showed nonspecific ST-T wave abnormality including some ST segment elevation and T wave inversion. In concert with elevated Troponin enzymes, there was concern for Myocarditis, pericarditis, and Non-ST elevation Myocardial Infarction.
Extensive immunological workup showed no evidence of consumption of complement, cryoglobulinemia, or a combination of clinical signs and symptoms along with serological workup, suggestive of rheumatological disease. There was an absence of a monoclonal spike on serum protein electrophoresis. Dermatological evaluation revealed a non-specific erythematous rash not suggestive of any infectious etiology, drug rash, vasculitis, or autoimmune disease. No biopsy was performed, and the rash faded away without specific treatment.

An increase in inflammatory markers with a bilinear decrease in cell lines, along with decreased reticulocyte count was suggestive of bone marrow suppression in response to an inflammatory process that resolved spontaneously as the clinical condition improved. Mild abdominal lymphadenopathy and mild splenomegaly were benign processes. Hemophagocytic lymphohistiocytosis was also considered but given the clinical improvement during serial follow-up, this was thought to be unlikely and bone marrow biopsy was not performed. Drug reaction with eosinophilia and systemic syndrome (DRESS) was considered unlikely after the application of the registry of severe cutaneous adverse reactions scoring system.

| Laboratory results on admission: | Result | Normal range |
|---------------------------------|--------|--------------|
| Leucocytes 12,400 WBC/ul. | 4.5–11.0 × 10^9/L |
| Thrombocytes 132,000/ul. | 150–400 × 10^9/L |
| Sodium 131 mmol/L | 136–146 mmol/L |
| Total bilirubin 2.8 mg/dL | 0.1–1.0 mg/dL |
| Direct bilirubin 2.3 mg/dL | 0.0–0.3 mg/dL |
| Alkaline phosphatase 175 U/L | 25–100 U/L |
| Troponin T enzyme baseline 135 ng/L | ≤15 ng/L |
| Troponin T enzyme at 2 h 155 ng/L | <10 ng/L |
| Troponin T enzyme at 6 h 180 ng/L | <12 ng/L |

| Laboratory results during hospitalization: | Result | Normal range |
|---------------------------------|--------|--------------|
| C-reactive protein 331 mg/L | ≤8 mg/L |
| Triglycerides 602 mg/dL | <150 mg/dL |
| Ferritin 4236 mcg/L | 20–250 µg/L |
| Lactate dehydrogenase 248 U/L | 45–200 U/L |
| Fibrinogen 780 mg/dL | 200–393 |
| Total bilirubin peak 9.3 mg/dL | ≤1.2 mg/dl |
| Direct bilirubin peak 9.2 mg/dL | 0.0–0.3 mg/dl |
| Alkaline phosphatase peak 448 U/L | 40–129 U/L |
| Blood urea nitrogen baseline 28 mg/dl | 6–24 mg/dL |
| Blood urea nitrogen peak 171 mg/dl | 8–24 mg/dL |
| Creatinine baseline 1.22 mg/dL | 0.6–1.2 mg/dL |
| Creatinine peak 8.22 mg/dL | 0.6–1.2 mg/dL |

Initial broad-spectrum antibiotics were deescalated to empiric doxycycline for a 10-day duration. 1/3 blood cultures were positive for coagulasenegative staphylococcus, which was categorized as a contaminant. SARS-CoV-2 nucleocapsid antibody was positive, consistent with a previous SARS-CoV-2 infection, however serial PCR testing remained negative throughout the hospitalization.

On the fourth day of hospitalization the patient was extubated and was noted to have prolonged metabolic encephalopathy secondary to multi-organ failure with EEG, MR imaging of the brain and CSF results being insignificant. Due to AKI requiring dialysis a renal biopsy was performed showing diffuse Acute tubular necrosis(ATN) and multifocal interstitial nephritis likely due to a combination of sepsis, hypotension, and NSAIDs (Fig. 3). The patient was initiated on a prednisone course with taper along with trimethoprim/sulfamethoxazole for pneumocystis jirovecii prophylaxis and his renal function eventually made a full recovery. IVIG were contraindicated due to myocardial dysfunction.

An extensive workup for multiple etiologies was negative, and hence a diagnosis of exclusion, MIS-V was made. The latter satisfies the CDC criteria and recently reported level 1 Brighton collaboration network for case definition of MIS-A/MIS-V. This severe adverse event following immunization was then reported to the United States Centers for Disease Control and Prevention (CDC).

3. Discussion

In a population-based surveillance study investigating adverse effects of mRNA vaccine using insurance company and electronic health records of patients in the USA, only six cases of MIS-V were
reported, when follow-up limited to 21 days post-vaccination was made after almost 12 million vaccine doses.9 Based on national passive surveillance data in the USA, the CDC published a report highlighting the characteristics and outcome of 20 patients with MIS-A and 7 cases of MIS-V in adults between December 2020 and April 2021.13 Patients demonstrated both a spike and nucleocapsid antibody after natural infection; this may however remain negative in mild cases in younger individuals or when PCR tests are falsely positive.13,14 Notably, all seven cases of MIS-V in adults had a prior history of SARS-CoV-2 infection or serological evidence of nucleocapsid antibody presence.13 More than 547 million doses of SARS-CoV-2 vaccine have been administered in the United States as of 15 February 2022[US Department of Health & Human Services, 2022 #207], with only very few cases of MIS-V reported in the five months of passive surveillance. Most of them have likely come to attention due to the severity of the illness, requiring ICU level support.13 Although deaths have been reported,15 these are exceedingly rare, and vaccination continues to be encouraged, as there is no direct evidence that the vaccine alone causes MIS without a previous natural infection.13,15

MIS-C/MIS-A/MIS-V are diagnoses of exclusion. After other causes were excluded, positive nucleocapsid antibody test could provide evidence for a MIS-A diagnosis, but the patient never had signs of infection.16 The only reported close contact exposure was seven months before presentation. To our knowledge, this is the first clinically descriptive case of MIS-V secondary to the use of Moderna mRNA-1273 vaccine in medical literature in an individual over 50 years of age. Like MIS-C and MIS-A, we still do not know the underlying pathophysiology of this syndrome. Various theories such as a dysregulated immune response to the vaccine with prior sensitization to SARS-CoV-2 infection leading to antibody-mediated cytokine storm, provoking autoimmunity have been proposed. Our patient had no prior autoimmune reactions. Corticosteroids and other immunomodulators can be used in MIS-V although these measures remain unproven.1,3,7,10,12,13,17 In our case, steroid treatment effectiveness remains inconclusive, as its initiation did coincide with potential spontaneous recovery from ATN.

This case highlights the possible serious adverse reactions to the COVID-19 vaccine. These reactions require further research investigating pathophysiological, acute, and long-term sequelae, and potential therapeutic options. The challenge for the future will be formulating diagnostic criteria, correctly identifying MIS-V, and differentiating it form MIS-A;4,5 such differentiation is important for research aimed at optimal clinical management.

4. Conclusion

MIS-V is a novel disease entity increasingly recognized during the course of the SARS-CoV-2 pandemic. The pathophysiology, risk factors, and management of this syndrome is a matter of ongoing research. Raising awareness is crucial to diagnosing this syndrome of exclusion.

Learning points

1) MIS has been described in children, adults and is now also being increasingly recognized as a rare complication in individuals receiving COVID-19 vaccination. The exact pathophysiology underlying this clinical syndrome remains unknown and is a matter of intense clinical research.

2) Emphasis is to be laid on clinical awareness and recognition, ruling out other differential diagnoses followed by good supportive therapy, often in an ICU, yielding favorable clinical outcomes. There has been some role for corticosteroids and IVIG, especially in children

3) Reporting and surveillance post-immunization needs to be robust in order to document the incidence and guide the public opinion and policymakers.

4) MIS-V likely occurs in individuals’ post-vaccination who are already primed immunologically with prior SARS-COV-2 infection.

Funding

This case report received support from “Mayo Clinic Health system” and “Mayo clinic, Rochester”.

Conflict of interest

The authors report there are no competing interests to declare.

Acknowledgements

Ying-Chun Lo, M.D., Ph. D, Senior associate consultant in Department of Pathology, Mayo Clinic Rochester for his help with Renal biopsy picture.

References

1. Morris SB, Schwartz NG, Patel P, et al. Case series of multi-system inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States,
March-August 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(40):1450–1456. https://doi.org/10.15585/mmwr.mm6940e1. PMID: 33031361 PMCID: PMC7561225 Journal Editors form for disclosure of potential conflicts of interest. Lilian Abbo reports personal fees from Pfizer, Merck/MSD, Nabiriva Therapeutics, Roche Diagnostics, Pareake, and Achoagen, outside the submitted work. Sharon E. Fox reports personal fees from Boehringer Ingelheim, outside the submitted work. Christopher Newton-Cheh reports grants from the National Institutes of Health, and personal fees from GE Healthcare, and Novartis, outside the submitted work. No other potential conflicts of interest were disclosed.

2. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and posed management. Children (Basel). 2020;7(7). https://doi.org/10.3390/children7070069. PMID: 32630212 PMCID: PMC7401880.

3. Nune A, Iyengar KP, Goddard C, Ahmed AE. Multisystem inflammatory syndrome in an adult following the SARSCoV-2 vaccine (MIS-V). BMJ Case Rep. 2021;14(7). https://doi.org/10.1136/ocr-2021-243888. PMID: 34326117 PMCID: PMC8323360.

4. Chow Ej. The multisystem inflammatory syndrome in adults with SARSCoV-2 infection—another piece of an expanding puzzle. JAMA Netw Open. 2021;4(5). e2110344. https://doi.org/10.1001/jamanetworkopen.2021.10394. PMID: 34009354 DOI: 10.1001/jamanetworkopen.2021.10394.

5. Davogusto GE, Clark DE, Hardison E, et al. Characteristics associated with multisystem inflammatory syndrome among adults with SARSCoV-2 infection. JAMA Network Open. 2021;4(5). https://doi.org/10.1001/jamanetworkopen.2021.10323. e2110323-e2110323.

6. Salzman MB, Huang CW, O’Brien CM, Castillo RD. Multisystem inflammatory syndrome after SARSCoV-2 infection and COVID-19 vaccination. Emerg Infect Dis. 2021;27(7):1944–1948. https://doi.org/10.3201/eid2707.210594. PMID: 34034858 PMCID: PMC8237872.

7. Uwaydah AK, Hassan NMM, Abu Ghoush MS, Shahin KMM. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Rep. 2021;14(4). https://doi.org/10.1136/bcr-2021-242060. PMID: 33883119 PMCID: PMC8061568.

8. U.S. Department of Health & Human Services. COVID-19 vaccinations in the United States”. “Center for disease Control. In: Website: center for disease Control. U.S. Department of Health & Human Services; 2022.

9. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. Jama. 2021;326(14):1390–1399. https://doi.org/10.1001/jama.2021.15072. PMID: 34477808 PMCID: PMC8511971 Centers for Disease Control and Prevention (CDC) during the conduct of the study, and grants from Pfizer, Merck, GSK, Sanofi Pasteur, and Protein Science (now SP) outside the submitted work. Ms Hanson reported receiving grants from CDC during the conduct of the study. Dr Donahue reported receiving grants from CDC during the conduct of the study and from Janssen Vaccines & Prevention for a study unrelated to COVID-19 vaccines. Dr Khurban reported receiving other from CDC (contract 200-2012-53526) during the conduct of the study. Dr Nalayway reported receiving grants from CDC during the conduct of the study and grants from Pfizer outside the submitted work. Dr Nelson reported receiving grants from Moderna outside the submitted work. Dr Williams reported receiving grants from CDC Vaccine Safety Datalink COVID-19 Infrastructure Funding during the conduct of the study. Dr Lewin reported receiving grants from CDC Vaccine Safety Datalink during the conduct of the study. No other disclosures were reported.

10. Iyengar KP, Nune A, Ish P, Botchu R, Shashidhara MK, Jain VK. Multisystem inflammatory syndrome after SARS-CoV-2 vaccination (MIS-V), to interpret with caution. Postgrad Med J. 2021. https://doi.org/10.1136/postgradmedj-2021-140869. PMID: 34446448.

11. Park JW, Yu SN, Chang SH, Ahn YH, Jeon MH. Multisystem inflammatory syndrome in an adult after COVID-19 vaccination: a case report and literature review. J Korean Med Sci. 2021;36(45). 0.

12. Vogel TP, Top KA, Karatzios C, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39(22):3037–3049. https://doi.org/10.1016/j.vaccine.2021.01.054. PMID: 33640145 PMCID: PMC7904456.

13. Belay ED, Godfred Cato S, Rao AK, et al. Multisystem inflammatory syndrome in adults after SARS-CoV-2 infection and COVID-19 vaccination. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciaa956. PMID: 34849680.

14. Houlihan CF, Beale R. The complexities of SARS-CoV-2 serology. Lancet Infect Dis. 2020;20(12):1350–1351. https://doi.org/10.1016/s1473-3099(20)30699-x. PMID: 32979317 PMCID: PMC7511169.

15. Grome HN, Threlkeld M, Threlkeld S, et al. Fatal multisystem inflammatory syndrome in adult after SARS-CoV-2 natural infection and COVID-19 vaccination. Emerg Infect Dis. 2021; 27(11):2914–2918. https://doi.org/10.3201/eid2711.211612. PMID: 34586059 PMCID: PMC8544993.

16. Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):206–213. https://doi.org/10.1093/infdis/jiaa273. PMID: 32427534 PMCID: PMC7313936.

17. Buchhorn R, Meyer C, Schulze-Foerster K, Junker J, Heidecke H. Autoantibody release in children after corona virus mRNA vaccination: a risk factor of multisystem inflammatory syndrome? Vaccines (Basel). 2021;9(11). https://doi.org/10.3390/vaccines9111353. PMID: 34835284 PMCID: PMC8618727.